Mauro Boronat

Mauro Boronat


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Globalization and Health
Verified
Journal Article
Open access
PDF file
JLJulio Lopez-Bastida
Julio Lopez-Bastida
MBMauro Boronat
Mauro Boronat
JOJuan Oliva-Moreno
Juan Oliva-Moreno
WSWillemien Schurer
Willemien Schurer
Diabetes is becoming of increasing concern in Spain due to rising incidence and prevalence, although little information is known with regards to costs and outcomes. The information on cost of diabetes in Spain is fragmented and outdated. Our objective is to update diabetes costs, and to identify outcomes and quality of care of diabetes in Spain.

14 August 2019 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
DADácil Alvarado-Martel
Dácil Alvarado-Martel
MFM. Ángeles Ruiz Fernández
M. Ángeles Ruiz Fernández
MVMaribel Cuadrado Vigaray
Maribel Cuadrado Vigaray
ACArmando Carrillo
Armando Carrillo
MBMauro Boronat
Mauro Boronat
AWAna M Wägner
Ana M Wägner
Purpose. To explore the factors involved in adherence to self-care behaviors in patients with type 1 diabetes. Materials and Methods. Patients with type 1 diabetes (age range: 14-71 years) were invited to participate at seven Spanish hospitals. They completed a dossier which recorded sociodemographic and clinical variables and also measured personality variables, emotional state, beliefs, and concerns regarding the illness, by means of questionnaires. Results. A total of 428 patients with type 1 diabetes were included (58% women, age 36 (11.8) years, diabetes duration 18.3 (10.2) years, HbA1c 7.9 +/-1.3%). A total of 60.1% of patients found it difficult to follow the treatment recommendations for the care of their disease. The reasons given were mood (25.2%), lack of motivation (13.4%), work (12%), and economic difficulties (3.8%). Other personal reasons were reported by 5.7%. Motivation, training in diabetes management, importance the patient attributed to the disease, and self-efficacy were the variables that predicted adherence to self-care behaviors, together accounting for 32% of its variance. Anxiety and depression were highly prevalent in this study population (57.1% and 23.1%, respectively) and were associated with lower adherence. Conclusion. In the present study assessing patients with type 1 diabetes, motivation, training in diabetes management, beliefs regarding the disease, and self-efficacy were the main contributors to adherence to self-care behaviors. On the other hand, anxiety and depression were highly prevalent and associated with lower adherence. Thus, supplementing therapeutic education with strategies designed to raise levels of motivation, discussion of beliefs about the disease, and encouragement of self-efficacy might be a useful way to increase patient involvement in self-care.

2 November 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
YRYolanda Ramallo-Fariña
Yolanda Ramallo-Fariña
MGMiguel A. García-Bello
Miguel A. García-Bello
LGLidia García-Pérez
Lidia García-Pérez
MBMauro Boronat
Mauro Boronat
AWAna M Wägner
Ana M Wägner
ITIndica Team
Indica Team
Background: Type 2 diabetes mellitus (T2DM) is a chronic disease in which health outcomes are related to decision making by patients and health care professionals. Objective: This study aims to assess the effectiveness of internet-based multicomponent interventions to support decision making of all actors involved in the care of patients with T2DM in primary care. Methods: The INDICA study is an open, community-based, multicenter trial with random allocation to usual care or the intervention for patients, the intervention for health care professionals in primary care, or the combined intervention for both. In the intervention for patients, participants received an educational group program and were monitored and supported by logs, a web-based platform, and automated SMS. Those in the intervention for professionals also received an educational program, a decision support tool embedded in the electronic clinical record, and periodic feedback about patients’ results. A total of 2334 people with T2DM, regardless of glycated hemoglobin (HbA1c) levels and without diabetes-related complications, were included. The primary end point was change in HbA1c level. The main analysis was performed using multilevel mixed models. Results: For the overall sample, the intervention for patients attained a significant mean reduction in HbA1c levels of ‒0.27 (95% CI ‒0.45 to ‒0.10) at month 3 and ‒0.26 (95% CI ‒0.44 to ‒0.08) at month 6 compared with usual care, which remained marginally significant at month 12. A clinically relevant reduction in HbA1c level was observed in 35.6% (191/537) of patients in the intervention for patients and 26.0% (152/586) of those in usual care at month 12 (P=.006). In the combined intervention, HbA1c reduction was significant until month 18 (181/557, 32.6% vs 140/586, 23.9%; P=.009). Considering the subgroup of patients uncontrolled at baseline, all interventions produced significant reductions in HbA1c levels across the entire study period: ‒0.49 (95% CI ‒0.70 to ‒0.27) for the intervention for patients, ‒0.35 (95% CI ‒0.59 to ‒0.14) for the intervention for professionals, and ‒0.35 (95% CI ‒0.57 to ‒0.13) for the combined intervention. Differences in HbA1c for the area under the curve considering the entire period were significant for the intervention for patients and the combined intervention compared with usual care (P=.03 for both). Compared with usual care, the intervention for professionals and the combined intervention had significant longer-term reductions in systolic and diastolic blood pressure. Conclusions: In uncontrolled patients, the intervention for patients at baseline provided clinically relevant and significant longer-term reductions of HbA1c levels. The intervention for professionals and combined intervention also improved the cardiovascular risk profile of patients. Trial Registration: ClinicalTrials.gov NCT01657227; https://clinicaltrials.gov/ct2/show/NCT01657227

8 September 2020 in Endocrine
Verified
Journal Article
Closed access
PDF file
MMMarta Morón-Díaz
Marta Morón-Díaz
PSPedro Saavedra
Pedro Saavedra
MAMaría P. Alberiche-Ruano
María P. Alberiche-Ruano
CRCarlos A. Rodríguez-Pérez
Carlos A. Rodríguez-Pérez
YLYaiza López-Plasencia
Yaiza López-Plasencia
MBMauro Boronat
Mauro Boronat

1 January 2012 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
MBMauro Boronat
Mauro Boronat
PSPedro Saavedra
Pedro Saavedra
NPNuria Perez
Nuria Perez
MLMaría J López-Madrazo
María J López-Madrazo
CRCarlos Rodríguez-Pérez
Carlos Rodríguez-Pérez
FNFrancisco J. Novoa
Francisco J. Novoa
Recent data suggest that concentrations of lipoprotein(a) [Lp(a)] may be inversely associated with the risk of diabetes. This study analyzed the relationships between Lp(a) and both diabetes and insulin resistance in an adult cohort from the island of Gran Canaria, Spain.

1 October 2019 in Atherosclerosis
Verified
Journal Article
Closed access
RSRosa M. Sanchez-Hernandez
Rosa M. Sanchez-Hernandez
MTMaria Donata Di Taranto
Maria Donata Di Taranto
AVAsier Benito vicente
Asier Benito vicente
KBKepa Belloso-Uribe
Kepa Belloso-Uribe
ILItziar Lamiquiz-Moneo
Itziar Lamiquiz-Moneo
GFGiuliana Fortunato
Giuliana Fortunato